Summarized by Masters of Longevity from Longevity Technology.
A news article previewing a biotech reanalysis that re-examines a Phase 2 multiple system atrophy trial and its biomarker-driven statistical approach. It invites readers curious about trial methods and the implications of post hoc adjustments for interpreting early-stage neurodegeneration studies.
Key Takeaways
- A Phase 2 trial of ATH434 in multiple system atrophy enrolled 77 adults and compared two doses versus placebo over one year.
- Post hoc adjustment for baseline CSF neurofilament light chain increased the 50 mg arm's estimated slowing of functional decline to 52%.
- The trial missed its primary substantia nigra iron imaging endpoint, with mixed regional iron changes across putamen, globus pallidus, and dentate nucleus.
